Previous 10 | Next 10 |
Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q3 earnings results on Friday, November 4th, before market open. The consensus EPS Estimate is $0.18 (-14.3% Y/Y) and the consensus Revenue Estimate is $562.17M (+6.3% Y/Y). Over the last 2 years, AMRX ha...
Amneal Pharmaceuticals ( NYSE: AMRX ) on Wednesday said it had received an abbreviated new drug application approval from the U.S. FDA for its leuprolide acetate injection to treat prostate cancer. AMRX expects to launch eight new injectables in 2022, the company said in a...
Company expects to launch 8 new injectables in 2022 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administrat...
Summary Shares of generic and specialty drug maker Amneal Pharmaceuticals, Inc. (AMPX) are down approximately 90% over the past four years as its attempt to transform itself has produced middling results. As the company pivots away from oral pills in favor of injectables, complex ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2022 financial results on Friday November 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern ...
First of three approved U.S. oncology biosimilars Amneal expects to launch Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS ® (bevacizumab-maly), a biosimilar referenci...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022. Mr. Pesquin joins the Company from Sanof...
Amneal Pharmaceuticals ( NYSE: AMRX ) has submitted a New Drug Application to the US FDA for IPX203 , carbidopa/levodopa (CD/LD) extended-release capsules for Parkinson’s disease. The application is based on phase 3 data that showed more "good on" time compared ...
- IPX203 is a novel, extended-release oral formulation of carbidopa and levodopa that if approved, would offer patients more “Good On” time with fewer doses Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (N...
- Newly launched Congressional Domestic Pharmaceutical Manufacturing Caucus will work to ensure a resilient supply chain of key medicines manufactured in the U.S. to strengthen our national security, particularly in light of the pandemic and recent geopolitical conflicts Amn...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...